Showing results (431-440 of 452) with videos related to
Sort By:
Pageof 46
Trials|July 26, 2022
The APPLE Tree programme: Active Prevention in People at risk of dementia through Lifestyle, bEhaviour change and Technology to build REsiliEnce-randomised controlled trialM Poppe, L Duffy, N L Marchant, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2022
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and EfficacyClaire N Harrison, Jacqueline S Garcia, Tim C P Somervaille, et al.Blood Advances|October 22, 2020
Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and responseOk-Kyong Chaekal, Andromachi Scaradavou, Emeline Masson Frenet, et al.Leukemia & Lymphoma|January 8, 2015
Phase I dose escalation study of lestaurtinib in patients with myelofibrosisElizabeth O Hexner, John Mascarenhas, Josef Prchal, et al.NEJM Evidence|August 26, 2025
Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 RearrangementSrdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M Vannucchi, et al.Cancer|December 7, 2017
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemiaGail J Roboz, Hagop M Kantarjian, Karen W L Yee, et al.Journal of Internal Medicine|August 25, 2004
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive ImpairmentB Winblad, K Palmer, M Kivipelto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2018
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid LeukemiaJeffrey E Lancet, Geoffrey L Uy, Jorge E Cortes, et al.Sleep Health|September 30, 2023
Distribution of dim light melatonin offset (DLMOff) and phase relationship to waketime in healthy adults and associations with chronotypeRebecca C Cox, Alivia B Blumenstein, Tina M Burke, et al.BMC Cancer|April 4, 2018
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemiaEhab Atallah, Charles A Schiffer, Kevin P Weinfurt, et al.Pageof 46